MF-094 is primarily used in research settings as a selective agonist for the farnesoid X receptor (FXR), which plays a crucial role in regulating bile acid, lipid, and glucose metabolism. Its application is significant in studying metabolic disorders such as diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). By activating FXR, MF-094 helps researchers understand the receptor's role in metabolic pathways and its potential as a therapeutic target. Additionally, it is utilized in preclinical studies to evaluate its efficacy in modulating cholesterol levels and improving insulin sensitivity, contributing to the development of novel treatments for metabolic and liver-related conditions.